Q3 FY2026
Filed Nov 9, 2026Q3 2026 net sales rose 27.0% to $151.1 million on Modern Oral growth, while GAAP net income fell 81.4% to $3.9 million and Adjusted EBITDA fell 41.3% to $18.4 million
Modern Oral sales more than doubled (gross sales +114.2%, net sales +102.9%) and total net sales grew 27.0%, but SG&A rose 69.1%, operating income fell to $9,870 thousand from $25,885 thousand, GAAP net income attributable to TPB fell 81.4%, and Adjusted EBITDA fell 41.3%. Full-year 2026 Modern Oral and Adjusted EBITDA guidance was reaffirmed, not raised.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total consolidated net sales, Q3 2026GAAP | $151.1M | – | 27.0% |
| Cost of sales, Q3 2026GAAP | $65.92M | – | – |
| Gross profit, Q3 2026GAAP | $85.17M | – | 20.9% |
| Consolidated gross margin (gross profit / net sales), Q3 2026GAAP | Not printed at consolidated level | – | – |
| Selling, general and administrative expenses, Q3 2026GAAP | $75.31M | – | 69.1% |
| Operating income, Q3 2026GAAP | $9.87M | – | – |
| Interest expense, net, Q3 2026GAAP | $4.24M | – | – |
| Income before income taxes, Q3 2026GAAP | $8.26M | – | – |
| Income tax expense, Q3 2026GAAP | $1.41M | – | – |
| Consolidated net income, Q3 2026GAAP | $6.85M | – | – |
| Net income attributable to Turning Point Brands, Inc., Q3 2026GAAP | $3.93M | – | decreased 81.4% |
| Basic EPS (net income attributable to TPB), Q3 2026GAAP | $0.20 | – | – |
| Diluted EPS, Q3 2026GAAP | $0.19 | – | – |
| Adjusted Diluted EPS, Q3 2026non-GAAP | $0.41 | – | – |
| Adjusted Net Income, Q3 2026non-GAAP | $8.31M | – | – |
| EBITDA, Q3 2026non-GAAP | $12.51M | – | – |
| Adjusted EBITDA, Q3 2026non-GAAP | $18.40M | – | decreased 41.3% |
| Modern Oral Gross Sales, Q3 2026other | $93.9M | – | increased 114.2% |
| Modern Oral Net Sales, Q3 2026other | $74.4M | – | increased 102.9% |
| Modern Oral Net Sales as share of total company Net Sales, Q3 2026other | 49.2% | – | – |
| Stoker's segment net sales, Q3 2026other | $113.8M | – | increased 52.0% |
| Stoker's segment gross profit, Q3 2026other | $63.7M | – | increased 41.5% |
| Stoker's segment gross profit as % of net sales, Q3 2026other | 56.0% | – | – |
| Zig-Zag segment net sales, Q3 2026other | $37.3M | – | decreased 15.5% |
| Zig-Zag segment gross profit, Q3 2026other | $21.4M | – | decreased 15.6% |
| Zig-Zag segment gross profit as % of net sales, Q3 2026other | 57.4% | – | – |
| Net cash provided by operating activities, nine months ended Sept 30, 2026GAAP | $9.45M | – | – |
| Capital expenditures, nine months ended Sept 30, 2026GAAP | −$7.11M | – | – |
| Consolidated net income, nine months ended Sept 30, 2026GAAP | $31.09M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Stoker's Products segmentCompany states growth was driven by triple-digit growth in Modern Oral. Gross margin fell to 56.0% from 60.2%, which the company says was primarily driven by a shift in product mix toward Modern Oral. | $113.8 million net sales (75% of total net sales in the quarter) | – | increased 52.0% |
| Zig-Zag Products segmentThe release does not state a cause for the decline. Segment gross profit decreased 15.6% to $21.4 million and gross margin was 57.4% versus 57.5%. | $37.3 million net sales (25% of total net sales in the quarter) | – | decreased 15.5% |
| Modern Oral (product line, reported within the Stoker's and total company figures)Company states Modern Oral accounted for 49.2% of total company Net Sales. Company cites investment in FRE and ALP for expanding distribution and consumer engagement. | $74.4 million net sales; $93.9 million gross sales | – | Net sales increased 102.9%; gross sales increased 114.2% |
FY 2026 (reaffirmed; previously updated September 21, 2026) outlook
- NoteFull year Modern Oral Gross Sales of $330-$350 million
- NoteFull year Modern Oral Net Sales of $260-$270 million
- NoteFull Year Adjusted EBITDA $70-$80 million (release wording: 'Full Year Adjusted EBITDA to $70-$80 million')
Capital returns
- Repurchased 167,161 shares for a total cost of $10.0M at an average price per share of $59.82 during Q3 2026.
- Cost of repurchased stock for nine months ended Sept 30, 2026: $(10,000) thousand.
- Payment of dividends for nine months ended Sept 30, 2026: $(4,830) thousand, versus $(4,089) thousand in the prior-year nine months.
- Equity offering proceeds for nine months ended Sept 30, 2026: $59,549 thousand, versus $97,499 thousand in the prior-year nine months.
- Tax distribution for nine months ended Sept 30, 2026: $(2,500) thousand.
What drove it
- Company states Gross Profit increased 20.9% to $85.2 million driven by Modern Oral growth.
- Company states SG&A increased 69.1% to $75.3 million, inclusive of Modern Oral-related sales and marketing investments and increased outbound freight costs.
- Company states Adjusted EBITDA decreased 41.3% to $18.4 million including increased sales and marketing investments.
- Company states Stoker's segment gross margin decline was primarily driven by a shift in product mix toward Modern Oral.
- Company reconciliation shows a non-GAAP add-back for FDA PMTA costs of $3,151 thousand in Q3 2026 versus $482 thousand in Q3 2025.
- Company reconciliation shows a non-GAAP add-back for manufacturing start-up costs of $593 thousand in Q3 2026, with no amount printed for Q3 2025.
- Adjusted Diluted EPS of $0.41 compares with a reported Q3 2025 figure of $1.05 on the same basis; Q3 2025 GAAP diluted EPS was $1.13, which included an ERC refund adjustment of $(4,284) thousand, per the Schedule B reconciliation.
Concerns
- GAAP net income attributable to Turning Point Brands, Inc. decreased 81.4% to $3,930 thousand, and Adjusted EBITDA decreased 41.3% to $18,401 thousand.
- Operating income fell to $9,870 thousand from $25,885 thousand while SG&A rose 69.1% to $75,305 thousand.
- Stoker's segment gross margin declined to 56.0% from 60.2%, which the company attributes to Modern Oral mix.
- Zig-Zag segment net sales decreased 15.5% to $37.3 million, and no cause is given in the release.
- Net cash provided by operating activities for nine months ended Sept 30, 2026 was $9,449 thousand, versus $32,515 thousand in the prior-year nine months.
- Inventories rose to $139,380 thousand from $107,989 thousand at December 31, 2025.
- FDA PMTA costs excluded from Adjusted EBITDA were $3,151 thousand in Q3 2026 versus $482 thousand in Q3 2025.
What to watch
- Delivery against the reaffirmed FY 2026 guidance: Modern Oral Gross Sales $330-$350 million, Modern Oral Net Sales $260-$270 million, and Adjusted EBITDA $70-$80 million.
- Gross margin trend in the Stoker's segment as Modern Oral mix increases.
- SG&A and sales and marketing spend relative to Modern Oral sales growth, given the 69.1% SG&A increase.
- Size of the gap between GAAP and Adjusted figures, including FDA PMTA costs and manufacturing start-up costs.
- Operating cash flow and inventory levels for the full year, given the nine-month operating cash flow decline.
- Zig-Zag segment net sales trajectory after a 15.5% decline in the quarter.
- Full Q3 2026 results in the Form 10-Q, which the release says may differ from these preliminary figures.
Balance sheet and cash flow
- Cash at September 30, 2026: $251.3 million ($251,290 thousand unrestricted), versus $222,760 thousand at December 31, 2025.
- Net debt at September 30, 2026: $48.7 million (as printed in the release).
- Total liquidity at September 30, 2026: $322.8 million, which includes $71.5 million of asset backed revolving credit facility capacity.
- Notes payable and long-term debt: $294,405 thousand at September 30, 2026, versus $293,625 thousand at December 31, 2025.
- Inventories, net: $139,380 thousand at September 30, 2026, versus $107,989 thousand at December 31, 2025.
- Total assets: $846,651 thousand at September 30, 2026, versus $763,750 thousand at December 31, 2025.
- Total stockholders' equity: $449,665 thousand at September 30, 2026, versus $371,983 thousand at December 31, 2025.
- Net cash used in investing activities, nine months ended Sept 30, 2026: $(22,271) thousand, versus $(28,384) thousand in the prior-year nine months.
- Net cash provided by financing activities, nine months ended Sept 30, 2026: $41,199 thousand, versus $148,250 thousand in the prior-year nine months.
- Net increase in cash, nine months ended Sept 30, 2026: $28,377 thousand, versus $152,381 thousand in the prior-year nine months.
- Reconciliation of Adjusted EBITDA for Q3 2026 includes FDA PMTA costs of $3,151 thousand versus $482 thousand in Q3 2025, and stock based compensation of $920 thousand versus $1,884 thousand.
Analysis
Turning Point Brands reported Q3 2026 net sales of $151,096 thousand, up 27.0% from $118,979 thousand, with the company attributing the growth to Modern Oral. Modern Oral gross sales were $93.9 million (up 114.2%) and net sales were $74.4 million (up 102.9%), which the company says represented 49.2% of total company Net Sales. Stoker's segment net sales rose 52.0% to $113.8 million, while Zig-Zag segment net sales fell 15.5% to $37.3 million. The release does not state a cause for the Zig-Zag decline.
Gross profit rose 20.9% to $85,175 thousand. The Stoker's segment gross margin declined to 56.0% from 60.2%, which the company says was primarily driven by a shift in product mix toward Modern Oral. Zig-Zag gross margin was broadly stable at 57.4% versus 57.5%. Consolidated gross margin is not printed as a percentage in the release.
Below gross profit, the figures moved sharply lower. SG&A rose 69.1% to $75,305 thousand, which the company says reflects Modern Oral sales and marketing investments and higher outbound freight. Operating income fell to $9,870 thousand from $25,885 thousand. Income tax expense was $1,414 thousand versus $6,472 thousand, and consolidated net income was $6,848 thousand versus $23,757 thousand. Net income attributable to Turning Point Brands, Inc. decreased 81.4% to $3,930 thousand, and GAAP diluted EPS was $0.19 versus $1.13. On the company's non-GAAP basis, Adjusted EBITDA decreased 41.3% to $18,401 thousand and Adjusted Diluted EPS was $0.41 versus $1.05. The Q3 2025 GAAP diluted EPS of $1.13 included an ERC refund of $(4,284) thousand in its Adjusted Diluted EPS reconciliation, so the prior-year GAAP and adjusted figures are not on a comparable basis.
Capital allocation in the quarter included share repurchases of 167,161 shares for $10.0 million at an average of $59.82. Cash was $251.3 million and net debt was $48.7 million. Nine-month operating cash flow was $9,449 thousand versus $32,515 thousand, and inventories increased to $139,380 thousand from $107,989 thousand at December 31, 2025. Total liquidity was $322.8 million including $71.5 million of asset backed revolving credit facility capacity.
Guidance was reaffirmed, not raised. The FY 2026 targets are Modern Oral Gross Sales of $330-$350 million, Modern Oral Net Sales of $260-$270 million, and Adjusted EBITDA of $70-$80 million, as updated on September 21, 2026. The release does not print a total revenue guide or a gross margin guide. The figures to watch are the Stoker's gross margin, the SG&A ratio, and the FDA PMTA and manufacturing start-up costs that management excludes from Adjusted EBITDA.
Management, verbatim
We delivered another quarter of strong results, highlighted by continued growth in Modern Oral and progress across our heritage brands.
David Glazek, Chief Executive Officer
Our investments in FRE and ALP are expanding distribution, strengthening consumer engagement and positioning us to become a leading player in the rapidly growing nicotine pouch category.
David Glazek, Chief Executive Officer
Not in the filing
stated, not guessed- Prior-year and prior-quarter figures for Modern Oral Gross Sales and Modern Oral Net Sales are not printed.
- Consolidated gross margin percentage is not printed for Q3 2026 or Q3 2025.
- Percentage change for cost of sales, operating income, interest expense, income before taxes, income tax expense, consolidated net income, GAAP diluted EPS, basic EPS, Adjusted Net Income, EBITDA, and Q3 2025 values for nine-month lines are not printed.
- Prior-quarter (Q2 2026) figures are not provided in the release, so all qoq_change and prior_quarter fields are null.
- Nine-month prior-year comparisons for income statement lines are not in the release, which presents three-month income statement data only.
- Cash and balance sheet change percentages are not printed for the nine-month period.
- Stock price reaction, consensus estimates and analyst expectations are not present in the filing.
- Zig-Zag segment cause of the 15.5% decline is not stated.
- Full-year 2026 total revenue, gross margin, operating expense and tax rate guidance are not printed.
- Prior-year Q3 2025 operating expense detail beyond SG&A is not printed.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.